IPO Year: 2023
Exchange: NASDAQ
10-Q - BullFrog AI Holdings, Inc. (0001829247) (Filer)
8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)
424B5 - BullFrog AI Holdings, Inc. (0001829247) (Filer)
SCHEDULE 13G/A - BullFrog AI Holdings, Inc. (0001829247) (Subject)
10-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)
8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)
SCHEDULE 13G - BullFrog AI Holdings, Inc. (0001829247) (Subject)
8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)
8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)
8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)
GAITHERSBURG, Md., April 17, 2025 (GLOBE NEWSWIRE) -- Bullfrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, is pleased to invite investors to a webinar on April 23, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Vin Singh, CEO of Bullfrog AI. Attendees will gain insight into Bullfrog AI's innovative use of artificial intelligence and machine learning to revolutionize drug development. The Company's proprietary bfLEAP™ platform, developed at Johns Hopk
GAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its entry into a collaboration agreement with Eleison Pharmaceuticals Inc. ("Eleison"), a Phase 3 oncology company focused on novel chemotherapeutic treatments for rare cancers. Under the terms of the agreement, BullFrog AI will provide access to its BullFrog Data Networks™ AI solution to enhance clinical trial efficiency and patient insights. Financial terms of the coll
GAITHERSBURG, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its participation in the TechBio track at Biotech Showcase and RESI JPM, both taking place during the annual JP Morgan Healthcare Conference in San Francisco, January 13–16, 2025. At both Biotech Showcase and RESI JPM, BullFrog AI will highlight its proprietary BullFrog Data Networks®, a data insights tool powered by the bfLEAP™ platform. BullFrog Data Networks® eva
GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to stockholders from its CEO Vin Singh. Dear Fellow Stockholders, As the year comes to a close, I want to extend my deepest gratitude for your unwavering support and belief in our mission to revolutionize drug development. Your commitment fuels our drive to innovate and achieve transformational milestones. In thinking back on this past year, it is evident that 2024 wa
GAITHERSBURG, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Josh Blacher as its Chief Financial Officer (CFO), effective immediately. This appointment comes in the wake of the untimely passing of Dane Saglio, BullFrog AI's former CFO, who recently lost his battle with cancer. "Dane's contributions to BullFrog AI were immeasurable. Beyond his exceptional expertise and dedication, Dane was a trusted advisor and
GAITHERSBURG, Md., Oct. 22, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ:BFRG, BFRGW))) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its VP Artificial Intelligence, Enrique García-Rivera, Ph.D., will present at Google's inaugural Cancer AI Symposium on October 30, 2024, at the Boston Center for the Arts. Dr. García-Rivera's presentation will showcase BullFrog AI's groundbreaking use of artificial intelligence in drug discovery and development. Highlighting the Company's proprietary bfLEAP™ platform, the pres
JERSEY CITY, N.J., Oct. 21, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW))) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today it has closed its previously announced definitive agreement for the purchase and sale of an aggregate of 1,565,000 shares of common stock (or common stock equivalents in lieu thereof) in a registered direct offering and, in a concurrent private placement, com
GAITHERSBURG, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW))) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today it has closed its previously announced definitive agreement for the purchase and sale of an aggregate of 1,565,000 shares of common stock (or common stock equivalents in lieu thereof) in a registered direct offering and, in a concurrent private placement, common warrants to purchase up to 1,565,000 shares of common stock (together with the registered direct offering) at
JERSEY CITY, N.J., Oct. 18, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW))) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, has entered into a definitive agreement for the purchase and sale of an aggregate of 1,565,000 shares of common stock (or common stock equivalents in lieu thereof) in a registered direct offering and, in a concurrent private placement, common warrants to purchase up to 1,565,00
GAITHERSBURG, Md., Oct. 18, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW))) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today it has entered into a definitive agreement for the purchase and sale of an aggregate of 1,565,000 shares of common stock (or common stock equivalents in lieu thereof) in a registered direct offering and, in a concurrent private placement, common warrants to purchase up to 1,565,000 shares of common stock (together with the registered direct offering) at a combined purch
ORLANDO, FL / ACCESSWIRE / April 26, 2024 / RedChip Companies will air interviews with BullFrog AI Holdings, Inc. (NASDAQ:BFRG) and GreenPower Motor Company Inc. (NASDAQ:GP) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, April 27, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BullFrog AI: https://www.redchip.com/assets/access/bfrg_accessGreenPower: https://www.redchip.com/assets/access/gp_accessIn an exclusive interview, Vin Singh, CEO of BullFrog AI, appears on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV to provide a corporate u
ORLANDO, FL / ACCESSWIRE / October 27, 2023 / RedChip Companies will air interviews with ASP Isotopes Inc. (NASDAQ:ASPI) and BullFrog AI Holdings, Inc. (NASDAQ:BFRG)(NASDAQ:BFRGW) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, October 28, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ASP Isotopes: https://www.redchip.com/assets/access/aspi_accessBullfrog AI: https://www.redchip.com/assets/access/bfrg_accessPaul Mann, CEO, of ASP Isotopes appears on the RedChip Small Stocks Big Money® Show on Bloomberg TV to provide a corporate update. ASP Isoto
New podcast series shines a spotlight on undervalued small-cap and microcap stocksORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap companies,announce the launch of its much-anticipated podcast series, "Small Stocks, Big Money."Hosted by RedChip CEO Dave Gentry and Associate Director Barrett Boone, the "Small Stocks, Big Money" podcast aims to offer a first-hand look at undiscovered small-cap and microcap stocks before they catch the attention of bigger Wall Street players. The series features in-depth interviews with executives from some of the top names in smaller cap stocks, providing list
ORLANDO, FL / ACCESSWIRE / May 19, 2023 / RedChip Companies will air new interviews with Sharps Technology, Inc. (NASDAQ:STSS, STSSW))) and BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW))) on The RedChip Money Report® on Bloomberg TV, this Saturday, May 20, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Sharps Technology, Inc.: https://www.stssinfo.com/interview_accessBullFrog AI Holdings, Inc.: https://bfrginfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' ex
ORLANDO, FL / ACCESSWIRE / April 14, 2023 / RedChip Companies will air interviews with BullFrog AI (NASDAQ:BFRG) and Alarum Technologies Ltd. (NASDAQ:ALAR) on The RedChip Money Report® on Bloomberg TV, this Saturday, April 15, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BullFrog AI (NASDAQ:BFRG): https://bfrginfo.com/interview_accessAlarum Technologies Ltd. (NASDAQ:ALAR): https://alarinfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' experience focused on Di
ORLANDO, FL / ACCESSWIRE / April 5, 2023 / RedChip Companies will air new interviews with BullFrog AI (NASDAQ:BFRG) and Sharps Technology (NASDAQ:STSS) on The RedChip Money Report® on Bloomberg TV, this Saturday, April 8, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BullFrog AI (NASDAQ:BFRG): https://bfrginfo.com/interview_accessSharps Technology (NASDAQ:STSS): https://www.stssinfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' experience focused on Discoverin
GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to stockholders from its CEO Vin Singh. Dear Fellow Stockholders, As the year comes to a close, I want to extend my deepest gratitude for your unwavering support and belief in our mission to revolutionize drug development. Your commitment fuels our drive to innovate and achieve transformational milestones. In thinking back on this past year, it is evident that 2024 wa
GAITHERSBURG, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Josh Blacher as its Chief Financial Officer (CFO), effective immediately. This appointment comes in the wake of the untimely passing of Dane Saglio, BullFrog AI's former CFO, who recently lost his battle with cancer. "Dane's contributions to BullFrog AI were immeasurable. Beyond his exceptional expertise and dedication, Dane was a trusted advisor and
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ:BFRG, BFRGW))) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of John Baldoni, Ph.D., to its Scientific Advisory Board. Dr. Baldoni brings over four decades of experience in the pharmaceutical industry, including leadership roles in scientific research and technology-driven drug discovery. Dr. Baldoni's career includes 29 years in R&D at GSK, where he served as Senior Vice President of Platform and Technology Sciences, lea
The study, led by Dr. Lopa Mishra and published in Cell Reports, provides new mechanistic evidence for role of BF-114 target β2-spectrin in obesity, MASLD, MASH, and HCCThe findings suggest that targeting β2-spectrin with BF-114 can prevent the progression of liver diseasesNew data builds on earlier studies and further supports BF-114's potential to address major unmet needs in treating obesity-related liver diseasesDr. Lopa Mishra, a globally recognized expert in liver disease, has joined BullFrog AI's Scientific Advisory Board to provide strategic insights for advancing BF-114 GAITHERSBURG, Md., Oct. 09, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW))) ("BullFr
GAITHERSBURG, Md., Feb. 26, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW))) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Dr. Thomas W. Chittenden, PhD, DPhil, PStat, as its new Chief Scientific Officer. With a distinguished career at the intersection of artificial intelligence, machine learning, drug discovery, and biostatistics, Dr. Chittenden brings a wealth of experience and a proven track record of leadership in scientific research and development to BullFrog AI. W
GAITHERSBURG, Md., Jan. 26, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW))) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of two distinguished scientific advisors to its advisory board: Gwenn S. Smith, PhD, and Jeremiah Wala, MD, PhD. "We are thrilled to welcome Dr. Smith and Dr. Wala to our advisory board," said Vin Singh, CEO of BullFrog AI. "Their remarkable achievements and deep knowledge in their respective fields will be invaluable as we continue to push the boundari
GAITHERSBURG, Md., July 11, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW))) ("BullFrog AI" or the "Company"), a precision medicine company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Enrique García-Rivera, Ph.D., as its new Vice President of Artificial Intelligence. The appointment will further advance BullFrog AI's best-in-class proprietary bfLEAP™ AI platform that is engineered to enable more accurate predictions of patient disease progression and improve the design of clinical trials to speed safe and effective drug development. "We are excite
GAITHERSBURG, Md., June 07, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW))) ("BullFrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, today announced the appointment of Toby Sayre, MS as VP of Business Development. Sayre brings more than 18 years of experience in life sciences and biotechnology consulting, business development, product development, and client engagement to BullFrog AI. He holds master's degrees in Cell and Molecular Biology and Biochemistry from San Francisco State University (SFSU) and University of California, Los Angeles (UCLA), and has a technical background in bioinfor
4 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)
4 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)
5 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)
5 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)
5 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)
4 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)
4 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)
3 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)
4 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)
4 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)